Results 161 to 170 of about 79,953 (279)

Toxic mechanisms of amyloid oligomers and therapeutic strategies

Protein Science, Volume 35, Issue 4, April 2026.
Abstract Amyloid oligomers are increasingly recognized as the major toxic contributors across protein‐misfolding disorders. In this review, we cover mechanistic evidence showing how these transient and structurally heterogeneous oligomers disrupt cellular homeostasis by: (i) permeabilizing lipid membranes and forming ion‐conducting pores; (ii ...
Magdalena I. Ivanova, Carmelo La Rosa, Ayyalusamy Ramamoorthy   +2 more
wiley   +1 more source

Primary (AL) Amyloidosis Following COVID-19 Infection: A Case Report. [PDF]

Clin Case Rep
Gholami N, Tahsini Tekantapeh S, Khalaji A, Nejati B, Ravaei G.   +4 more
europepmc   +1 more source

Overproduction of 42 Amino Acids Long Amyloid Beta Leads to Activation of Secretory Autophagy and Development of Drusen‐Like Structures Originating From Retinal Pigment Epithelium

The FASEB Journal, Volume 40, Issue 5, 15 March 2026.
The role of 42 amino acids long amyloid beta (Aβ) in the retinal pigment epithelium (RPE) was investigated using 5xFAD mice model overproducing Aβ. The RPE cells of 5xFAD mice showed increased oxidative stress, accumulation of autophagy‐destined proteins, increased expression of secretory autophagy markers, and increase in epithelial‐to‐mesenchymal ...
Johanna Ruuth, Toni Tamminen, Elisa Toropainen, Heikki Tanila, Juha M. T. Hyttinen, Tarja Malm, Kai Kaarniranta, Ali Koskela   +7 more
wiley   +1 more source

Primary (AL) Amyloidosis

Renal Failure, 1993
openaire   +2 more sources

Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease

Advanced Materials, Volume 38, Issue 17, 20 March 2026.
RNA interference (RNAi) nanomedicine revolutionizes treatment regimens for ischemic heart diseases by enabling tailored, sequence‐anchored gene regulation. This review highlights the recent advances in nanotechnology‐driven RNAi therapeutics for myocardial ischemia and discusses the key design principles that govern efficient delivery, providing ...
Han Gao, Da Pan, Hélder A. Santos
wiley   +1 more source

A Case of AL Amyloidosis With Hepatomegaly as the Main Clinical Manifestation. [PDF]

Clin Case Rep
Dong S, Lv R, Wang W, Gao G, Zhao M, Ma X.   +5 more
europepmc   +1 more source

Photo‐Catalyzed Labeling of Amyloid Deposits in Human Tissue to Proteotype Amyloidosis Diseases

Aggregate, Volume 7, Issue 3, March 2026.
Amyloid‐ID, a ThT‐like photocatalytic probe, enables proteotyping of amyloid deposits by ROS‐mediated protein labeling. Applied to patient biopsies, amyloid‐ID identifies potential fibrinogen‐derived amyloid in laryngeal amyloidosis, revealing a mechanically sensitive fibrillation mechanism linked to vocal cord friction.
Huan Feng, Fangliang Guo, Yan Wang, Meng You, Qiuxuan Xia, Wang Wan, Di Shen, Kaini Shen, Xin Zhang, Wei Li, Yu Liu   +10 more
wiley   +1 more source

AL amyloidosis: a real-world experience with CAR T-cell therapy. [PDF]

Blood Adv
Tan MSY, Warsame R, Parrondo R, Muchtar E, Kourelis T, Buadi F, Gonsalves W, Cook J, Kapoor P, Hayman S, Dingli D, Binder M, Leung N, Roy V, Sher T, Wiedmeier-Nutor JE, Chhabra S, Fonseca R, Abdallah N, Rajkumar SV, Kumar SK, Gertz M, Lin Y, Dispenzieri A.   +23 more
europepmc   +1 more source

Zolpidem restores sleep and decreases amyloid in a mouse model

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Deficits in non–rapid eye movement (NREM) sleep facilitate Alzheimer's disease (AD) progression. Enhancing gamma‐aminobutyric acid‐ergic (GABAergic) signaling can restore sleep. Unbiased computational analysis identified zolpidem as high‐affinity GABA receptor modulator facilitating chloride transport that could slow AD.
Lu Yu, Shinya Yokomizo, Tri H. Doan, Qiuchen Zhao, Akshatha Ganne, Meenakshisundaram Balasubramaniam, Ksenia V. Kastanenka   +6 more
wiley   +1 more source

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients. [PDF]

Hemasphere
Bellofiore C, Basset M, Nuvolone M, Nanci M, Sanna GD, Di Simone VA, Fogliani A, Di Cecca M, Mussinelli R, Foli A, Ghazi Esfahani M, Sadrzadeh M, Perlini S, De Luca L, Clavreul S, Merlini G, Palladini G, Milani P.   +17 more
europepmc   +1 more source